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TCT-59
Concomitant use of clopidogrel and proton pump inhibitors and major adverse
cardiovascular events following coronary stent implantation
Morten Schmidt1, 2, Martin B Johansen1, Douglas J Robertson4, Michael Maeng2,
Anne Kaltoft2, Lisette O Jensen5, Hans-Henrik Tilsted6, Hans Erik Bøtker2, Henrik
Toft Sørensen1, John A Baron3
1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus,
Denmark; 2Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus,
Denmark; 3Department of Medicine University of North Carolina School of
Medicine, Chapel Hill, NC; 4VA Medical Center, White River Junction, VT, and
Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH;
5Department of Cardiology, Odense University Hospital, Odense, Denmark;
6Department of Cardiology, Aarhus University Hospital, Aalborg, Aalborg, Denmark
Background: The interaction between clopidogrel and proton pump inhibitors (PPIs)
has not been examined using time-varying drug exposure ascertainment among patients
treated with coronary stents. We examined whether PPI use modified the association
between clopidogrel use and major adverse cardiovascular events (MACE) after
coronary stent implantation.
Methods: We conducted this population-based cohort study in Western Denmark
(population 3 million) using medical databases. We identified all 13,001 patients with
coronary stent implantation between 2002 and 2005 and ascertained their
comorbidities. During the recommended 12-month postintervention treatment period,
we tracked use of clopidogrel and PPI and the rate of MACE. We used Cox regression
to compute hazard ratios, controlling for potential confounders.
Results: The rate of MACE was 154 per 1000 person years for concomitant clopidogrel
and PPI use, 104 for clopidogrel without PPI use, 267 for PPI without clopidogrel use,
and 263 for no use of either drug. The adjusted hazard ratio for MACE comparing
clopidogrel use with non-use was 0.57 (95% confidence interval: 0.44-0.74) among
PPI users and 0.47 (95% confidence interval: 0.42-0.53) among PPI non-users, yielding
an interaction effect (i.e., relative rate increase) of 1.20 (95% confidence interval: 0.91-
1.58). The adjusted hazard ratio for MACE, comparing PPI use with non-use, was 1.40
(95% confidence interval: 1.17-1.68) among clopidogrel users and 1.16 (95%
confidence interval: 0.95-1.43) among clopidogrel non-users.
Conclusion: Clopidogrel use was associated with a markedly reduced rate of MACE
within 12 months after coronary stent implantation, independent of PPI use. PPI use
did not modify the protective effect of clopidogrel substantially, but was associated
with MACE itself.
TCT-60
Protective Effects of Ranolazine Before Elective Percutaneous Coronary
Intervention: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Francesco Pelliccia1, Giuseppe Marazzi2, Vincenzo Pasceri1, Alessio Arrivi3,
Gaetano Tanzilli3, Enrico Mangieri3, Carlo Gaudio3, Giuseppe Mercuro4
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3University La Sapienza, Rome, Italy; 4University of Cagliari, Cagliari, Italy
Background: Ranolazine is a novel antianginal drug that reduces intracellular sodium
and calcium accumulation during ischemia thus limiting ischemic injury. It remains
unknown, however, if the drug can play a role in the pathophysiology of small
myocardial infarctions after percutaneous coronary intervention (PCI). Aim of this
study was to verify in a randomized study if pre-treatment with ranolazine before PCI
has any protective effect.
Methods: Fifty patients with stable angina (32 men, age: 55+13 years) scheduled for
elective coronary intervention entered a randomized, double-blind, placebo-controlled
pilot trial. For 7 days prior to the procedure, 25 patients were assigned to receive
ranolazine (500 mg twice daily) and 25 patients had placebo. Creatine kinase-MB,
troponin-I and myoglobin levels were measured at baseline and at 8 and 24 hours post
procedure.
Results: Comparison between the two groups did not show any difference in age, sex,
risk factors, cardiac function, and extension of coronary artery disease. Also, there was
no difference in any technical aspect of PCI. Detection of markers of myocardial injury
above the upper normal limit was significantly lower in the ranolazine vs placebo
group: 12% vs 35% for creatine kinase-MB (p=0.001), 20% vs 48% for troponin-I
(p=0.0004) and 22% vs 51% for myoglobin (p=0.0005). Myocardial infarction by
creatine kinase-MB determination was less commonly seen after PCI in the ranolazine
than in the placebo-group (5% vs 18%, p=0.025). Postprocedural peak levels of creatine
kinase-MB (2.9+18 vs 7.5+18 ng/mL, p=0.0002) were also significantly lower in the
ranolazine vs placebo group. No significant side effect was reported by the two groups
of patients.
Conclusion: Pretreatment with ranolazine 500 mg twice daily for 7 days significantly
reduced procedural myocardial injury in elective PCI. These findings indicate that
ranolazine may provide a friendly protection to ischemic cardiomyocytes. A multicentre
randomized study is now ongoing and complete results will be available by 2012.
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TCT-61
Long Term Follow Up Of 4 Treatment Strategies in Multivessel Disease
Following Primary Percutaneous Intervention For Acute Myocardial Infarction
Pranobe Oemrawsingh1, 3, Shirida Imami1, Matthijs Bax1, 2, Carl Schotborgh1, 2,
Lucas Savalle1, 3, Jan Willem Bech1, 4, Arnout Haasdijk1, 3
1Cardiology, Heart Center The Hague-Delft, The Hague, Netherlands;
2HagaZiekenhuis, The Hague, Netherlands; 3MC Haaglanden, The Hague,
Netherlands; 4Reinier de Graaf Groep, Delft, Netherlands
Background: Multivessel disease (MVD) is present in ±50% of pts at primary PCI
for 1st acute myocardial infarction (AMI). The optimal treatment for significant non-
culprit lesions (NCL) is unclear. We compared long-term clinical outcome of 4 current
treatment strategies for AMI pts with MVD after primary percutaneous intervention
(PCI).
Methods: Of 1911 consecutive pts with AMI referred for primary PCI from 2006 to
2010, MVD was detected in 928 (48%) pts. Pts without prior AMI or bypass surgery
(CABG), shock or resuscitation were included in this analysis (n=856; 44%). At
primary PCI 68 (8%)pts also had PCI for all NCL (1-stage PCI; 66yr, ˛80%).
Scheduled 2-stage PCI was done in 130 (15%) pts (59 yr, ˛78%), 122(14%) pts (64
yr, ˛78%) had planned CABG and 539 (63%) pts (65 yr, ˛72%) had medical
treatment (MT) only. Follow up included mortality, re-AMI, repeat revascularization,
cerebrovascular accidents (CVA) and admission for heart failure.
Results: Pts in the 2-stage PCI group pts were significantly younger, whereas
hypertension was more prevalent in the CABG group. Mortality was 6% in 1-stage
PCI, 1% in 2-stage PCI, 2% in CABG and 5% in MT group at 1 yr (p=0.04). At 3 yr
follow up mortality was comparable in 1-stage PCI (7%), CABG (7%) and MT (8%)
groups, but lower in the 2-stage PCI group (2%; NS). Re-AMI and CVA were
significantly more frequent in the CABG group (9% and 6%) compared to the 1-stage
PCI group (5% and 2%), the 2-stage PCI group (2% and 0%) and the MT group (3%
and 2%; p=0.01 and p=0.02). No differences were found in admission for heart failure
up to 3 yrs.
Conclusion: Of 4 current treatment strategies for AMI pts with MVD, the planned
revascularization groups (2-stage PCI and CABG) had significant better survival
compared to 1-stage PCI or MT groups at 1 yr. Follow up extended up to 4 yr with
Kaplan-Meier survival plots will be presented. The present data support 2-stage PCI
as preferred treatment strategy for AMI patients with MVD. Prospective randomized
studies are needed to confirm these findings and provide tools to optimize long-term
outcome.
TCT-62
Culprit-lesion-only vs. Multivessel Revascularization Using Drug-eluting Stents
in ST-Segment Elevation Myocardial Infarction: A KAMIR-based Analysis
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5Kyungpook National University Hospital, Daegu, Republic of Korea; 6Keimyung
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Background: In patients with STEMI of multivessel disease, complete
revascularization for nonculprit lesions is not routinely recommended. The aim of this
study was to compare the clinical outcomes of multivessel disease compared with IRA-
only revascularization in patients undergoing primary PCI for STEMI.
Methods: From the Korean Acute Myocardial Infarction Registry (KAMIR) database,
1,094 STEMI patients with multivessel disease who underwent primary PCI with DES
were enrolled in this study. The patients were divided into two groups: culprit-vessel-
only revascularization (COR, n=986); multivessel revascularization, including non-IRA
(MVR, n=313). The primary endpoint of this study included major adverse cardiac
events (MACE), such as death, myocardial infarction, or target or nontarget lesion
revascularization at one year.
Results: There was no difference in clinical characteristics between the two groups.
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During one-year follow-up, 123 (15.2%) patients in the COR group and 40 (14.2%) in
the MVR group experienced at least one MACE (p=0.502). There were no differences
between the two groups in terms of rate of death, myocardial infarction, or
revascularization (2.1 vs. 2.0%, 0.7 vs. 0.8%, and 11.7 vs. 10.1%, respectively;
p=0.908, 0.908, and 0.540, respectively). The MACE rate was higher in the
incompletely revascularized patients than in the completely revascularized patients
(16.2 vs. 9.7%, p=0.017), and the difference was attributable to a higher rate of
nontarget vessel revascularization (8.6 vs. 1.8%, p=002).
Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not
reduce the MACE rate compared with culprit-vessel-only PCI, complete
revascularization was associated with a lower rate of revascularization after multivessel
PCI.
TCT-63
Treatment Of Multivessel Coronary Artery Disease In Primary PCI for
STEMI: Culprit Only Revascularisation is Associated with Higher MACE
Rates
Oliver Guttmann, Daniel A Jones, Krishnaraj Rathod, Roshan Weerackody, M.
Akthar, Eleanor Wicks, Ajay Jain, Charles Knight, Anthony Mathur, Andrew Wragg
Barts and the Royal London NHS Trust, London, United Kingdom
Background: Multi-vessel disease occurs in 40-65% of patients undergoing Primary
PCI for STEMI and is associated with adverse prognosis. There is limited data
comparing outcomes of complete with infarct-related artery (IRA)-only
revascularisation in primary PCI for STEMI. We therefore sought to clarify the
outcome for those patients dependent on management strategy.
Methods: Prospective data of 2131 STEMI patients was analysed, who underwent
primary PCI between January 2004 and May 2010. Information was entered at the time
of procedure and outcome assessed by all-cause mortality information. Patients were
split into three different treatment groups: culprit vessel angioplasty-only (COR group);
staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR
group). The primary end point used was MACE, defined as death, MI, stroke and TVR.
Results: There were 963 (45%) consecutive patients with STEMI and multivessel
CAD. There were similar baseline characteristics between the 3 groups, aside from
cardiogenic shock, which was significantly higher in the CR group. At 30 days of
follow up, 23/263 (9%) patients in the CR group experienced at least one major adverse
cardiac event (MACE), 1 (1%) in the SR group and 35 (5%) in the CR group (p=0.01).
This trend continued up to 1 year of follow up with the lowest rates of events in the
SR group. However after 3 years MACE rates are significantly increased in the COR
group (24%) but were similar in the CR (18%) and SR (17%) groups. MACE rates
were driven mainly by death in the CR with high rates of TVR in the COR and SR
groups.
Conclusion: Culprit vessel-only angioplasty was associated with the highest rate of
long-term MACE compared with multivessel treatment. Patients scheduled for staged
revascularisation experienced a similar rate of MACE to patients undergoing complete
simultaneous treatment of non-IRA.
TCT-64
Prasugrel Versus Double Clopidogrel to Overcome High Platelet Reactivity
Early Following a 600mg Clopidogrel Loading Dose In Patients Undergoing
Primary Percutaneous Coronary Intervention
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Konstantinos Theodoropoulos,
George Kassimis, Theodora Plakomyti, Anastasia Galati, Grigorios Tsigkas, Ioannis
Chiladakis, Periklis Davlouros, George Hahalis
Cardiology Department, Patras University Hospital, Patras, Greece
Background: Platelet reactivity (PR) assessment in the very early phase (2 hours post
600mg clopidogrel loading dose-LD) of ST-elevation myocardial infarction (STEMI)
has not been previously reported nor any possible ways to overcome high on-treatment
PR (HTPR).
Methods: In STEMI patients undergoing primary PCI, PR was assessed with the
VerifyNow (Accumetrics Inc., San Diego, CA, USA) assay 2 hours after a 600mg
clopidogrel LD. Patients with HTPR (≥ 235 PR Units), were randomized to either
immediate reloading with 60mg prasugrel/10mg maintenance dose (MD) (group-A)
or clopidogrel 150mg MD starting from the next day (group-B). PR was re-assessed
at 2, 24 hours and at 5 days following randomization. Genotyping was performed for
CYP2C19*2 carriage.
Results: Out of 59 STEMI patients, 38(64.4%) demonstrated HTPR 2 hours post LD
and were all randomized (19 group-A and 19 group-B). PR 2 hours, 24 hours and 5
days post randomization was lower in group-A compared to group-B (Figure 1). HTPR
rate was lower for group-A compared to group-B at 24 hours post randomization in all
patients, in non-carriers and in carriers of 1 CYP2C19*2 loss-of-function allele (5.3%
vs 63.2%, p<0.001, 0% vs 57.1%, p=0.006 and 14.3% vs 100%, p=0.03 respectively).
Conclusion: In STEMI patients, HTPR 2 hours following 600 mg of clopidogrel LD
is very common. An additional reloading with 60 mg of prasugrel followed by a 10
mg MD, achieves greater platelet inhibition compared to clopidogrel 150 mg MD as
early as in 2 hours, a difference that is maintained up to 5 days.
TCT-65
Does Cytoprotector Mexicor Used Intracoronary during Rescue PCI Limit
Reperfusion Myocardial Injury in STEMI Patients?
Anton Koledinsky, Dmitry Gromov, Oleg Sukhorukov, Djamil Asadov, Natalia
Kuchkina, Pavel Vasiliev, David Iosseliani
Moscow City Center of Interventional Cardioangiology, Moscow, Russian
Federation
Background: To study the safety and efficacy of cytoprotector Mexicor (methyl-ethyl-
pyridinol succinate; EcoPharmInvest, Russia) used intracoronary in IRA followed by
angioplasty (stenting) within the first hours after the onset of STEMI.
Methods: The study comprised 191 STEMI patients (mean age 56±7) after successful
primary PCI of totally occluded (TIMI 0) IRA. Before PCI all patients were
randomized into two groups. Patients from Gr.1 (n=96) received 0,2 g of Mexicor in
100 ml of saline solution through microcatheter immediately after recanalization of
IRA before angioplasty. Gr.2 (n=95) comprised patients after successful PCI but
without intracoronary Mexicor use. Main baseline clinical, history and coronary
angiographic data were similar in all cases. Blood sampling for Troponine I was
performed prior to, and in 12 and 24 hours after the procedure. At day 10 as well as in
6 months all patients underwent repeat coronary angiography and left ventriculography.
Results: No complications related to intracoronary use of Mexicor were seen. Survival
during early follow-up was 98,06% in Gr.1 and 98,05% in Gr. 2. Total value of
Troponine I by 24th hour was 292,6±41,5 and 603,7±34,4 ng/ml, respectively (p<0,05).
At day 10 LV EF was 49,7±8,2 and 49,3±9,1, respectively In the mid-term (6,8±0,7
months) survival was 96,8% in Gr.1 and 92,7% in Gr. 2, LV EF was 53,1±9,4% and
48,7±8,3% (p<0,05).
Conclusion: The study suggests that the use of cytoprotector Mexicor intracoronary
in IRA immediately before angioplasty, in our opinion, is safe and limits reperfusion
B19JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/ORAL/STEMI
www.JACC.TCTAbstracts2011
O
R
A
L
S
